| Company/Division name | BioSpectra |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 100 |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 1995 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Bangor |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceutical ingredients |
| What non-domestic negative factors made offshoring less attractive? | Intellectual property risk, Quality/rework/warranty, Social/ethical concerns, Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Impact on domestic economy, Lead time/Time to market, Skilled workforce availability/training |
